Insights on methotrexate in psoriatic disease

Jacqueline E. Greb; Ari M. Goldminz; Alice B. Gottlieb

doi:10.1016/j.clim.2016.07.008

Insights on methotrexate in psoriatic disease

Jacqueline E. Greb, Ari M. Goldminz, Alice B. Gottlieb

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

The folic acid analogue methotrexate is used as an anti-neoplastic agent and treatment for inflammatory disorders including psoriasis, dermatomyositis, lupus erythematous, sarcoidosis, and systemic sclerosis. Despite the introduction of newer biologic agents, methotrexate remains a first-line systemic therapy for many patients with disorders of chronic inflammation. Here we briefly describe the current clinical evidence for methotrexate use in psoriatic disease, our current understanding of methotrexate's anti-inflammatory properties, and the future role of methotrexate in the treatment of immune mediated disorders.

Original language	English
Pages (from-to)	61-64
Number of pages	4
Journal	Clinical Immunology
Volume	172
DOIs	https://doi.org/10.1016/j.clim.2016.07.008
State	Published - 1 Nov 2016
Externally published	Yes

Keywords

Adenosine
Cardiovascular disease
Methotrexate
Psoriasis
Psoriatic arthritis
T-cell

Access to Document

10.1016/j.clim.2016.07.008

Cite this

@article{77a0d8f5bb344b7e9e2be6946c4894e7,

title = "Insights on methotrexate in psoriatic disease",

abstract = "The folic acid analogue methotrexate is used as an anti-neoplastic agent and treatment for inflammatory disorders including psoriasis, dermatomyositis, lupus erythematous, sarcoidosis, and systemic sclerosis. Despite the introduction of newer biologic agents, methotrexate remains a first-line systemic therapy for many patients with disorders of chronic inflammation. Here we briefly describe the current clinical evidence for methotrexate use in psoriatic disease, our current understanding of methotrexate's anti-inflammatory properties, and the future role of methotrexate in the treatment of immune mediated disorders.",

keywords = "Adenosine, Cardiovascular disease, Methotrexate, Psoriasis, Psoriatic arthritis, T-cell",

author = "Greb, {Jacqueline E.} and Goldminz, {Ari M.} and Gottlieb, {Alice B.}",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier Inc.",

year = "2016",

month = nov,

day = "1",

doi = "10.1016/j.clim.2016.07.008",

language = "English",

volume = "172",

pages = "61--64",

journal = "Clinical Immunology",

issn = "1521-6616",

publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Insights on methotrexate in psoriatic disease

AU - Greb, Jacqueline E.

AU - Goldminz, Ari M.

AU - Gottlieb, Alice B.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - The folic acid analogue methotrexate is used as an anti-neoplastic agent and treatment for inflammatory disorders including psoriasis, dermatomyositis, lupus erythematous, sarcoidosis, and systemic sclerosis. Despite the introduction of newer biologic agents, methotrexate remains a first-line systemic therapy for many patients with disorders of chronic inflammation. Here we briefly describe the current clinical evidence for methotrexate use in psoriatic disease, our current understanding of methotrexate's anti-inflammatory properties, and the future role of methotrexate in the treatment of immune mediated disorders.

AB - The folic acid analogue methotrexate is used as an anti-neoplastic agent and treatment for inflammatory disorders including psoriasis, dermatomyositis, lupus erythematous, sarcoidosis, and systemic sclerosis. Despite the introduction of newer biologic agents, methotrexate remains a first-line systemic therapy for many patients with disorders of chronic inflammation. Here we briefly describe the current clinical evidence for methotrexate use in psoriatic disease, our current understanding of methotrexate's anti-inflammatory properties, and the future role of methotrexate in the treatment of immune mediated disorders.

KW - Adenosine

KW - Cardiovascular disease

KW - Methotrexate

KW - Psoriasis

KW - Psoriatic arthritis

KW - T-cell

UR - http://www.scopus.com/inward/record.url?scp=84993940283&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2016.07.008

DO - 10.1016/j.clim.2016.07.008

M3 - Article

C2 - 27455859

AN - SCOPUS:84993940283

SN - 1521-6616

VL - 172

SP - 61

EP - 64

JO - Clinical Immunology

JF - Clinical Immunology

ER -

Insights on methotrexate in psoriatic disease

Abstract

Keywords

Access to Document

Fingerprint

Cite this